Houte Hans Van Sells 3,661 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 3,661 shares of the business’s stock in a transaction on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $60,772.60. Following the transaction, the chief financial officer directly owned 45,427 shares of the company’s stock, valued at $754,088.20. This trade represents a 7.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Monday, November 3rd, Houte Hans Van sold 6,284 shares of Nurix Therapeutics stock. The shares were sold at an average price of $12.56, for a total value of $78,927.04.

Nurix Therapeutics Stock Down 6.1%

Nurix Therapeutics stock opened at $16.52 on Friday. The stock has a market cap of $1.27 billion, a PE ratio of -5.43 and a beta of 1.93. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $22.50. The business’s 50-day moving average price is $18.50 and its two-hundred day moving average price is $13.37.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Wednesday, January 28th. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.02. The company had revenue of $13.58 million for the quarter, compared to the consensus estimate of $13.41 million. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. As a group, analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Hedge Funds Weigh In On Nurix Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in NRIX. Wexford Capital LP bought a new stake in Nurix Therapeutics in the third quarter valued at approximately $41,000. Tower Research Capital LLC TRC lifted its position in shares of Nurix Therapeutics by 118.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after purchasing an additional 3,475 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Nurix Therapeutics by 66.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,926 shares of the company’s stock worth $93,000 after purchasing an additional 1,970 shares during the period. Sherbrooke Park Advisers LLC bought a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at $100,000. Finally, 49 Wealth Management LLC acquired a new stake in shares of Nurix Therapeutics during the third quarter worth $108,000.

Analysts Set New Price Targets

A number of brokerages have recently commented on NRIX. Needham & Company LLC reiterated a “buy” rating and issued a $26.00 price target on shares of Nurix Therapeutics in a research note on Thursday. Wells Fargo & Company dropped their target price on Nurix Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Thursday. Piper Sandler lifted their price target on Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Thursday. Wall Street Zen downgraded Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, October 11th. Finally, HC Wainwright raised their price objective on shares of Nurix Therapeutics from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.50.

Nurix Therapeutics News Summary

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada raised its price target on NRIX to $30 and maintained an outperform view, signaling significant upside versus the current stock level. RBC increases price target to $30
• Positive Sentiment: Needham & Company reaffirmed a “buy” rating with a $26 target and BTIG reiterated a buy with a $30 target — multiple brokerages maintaining bullish outlooks provide support for upside expectations. Needham and BTIG ratings
• Negative Sentiment: Insiders sold shares on Jan. 30: Gwenn Hansen sold 4,895 shares at ~$16.60 and CFO Houte Hans Van sold 3,661 shares at ~$16.60. Insider sales can be viewed negatively by the market because they reduce insider ownership and may signal cashing out. SEC filings: Hansen Form 4 and Van Form 4
• Negative Sentiment: TipRanks highlighted a newly disclosed material foreign‑exchange risk for Nurix due to unhedged currency exposure, which could increase earnings volatility and raise capital‑markets uncertainty. TipRanks: FX risk disclosed

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.